W Wong1, P J Morris, K J Wood. 1. Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, United Kingdom.
Abstract
BACKGROUND: Allograft survival can be prolonged by the administration of alloantigen(s) before transplantation. Blood transfusion is the commonest form of alloantigen pretreatment currently used in clinical practice. However, for recipients of organs from cadaver donors, it is not possible to predict the identity of the organ donor in advance. Therefore, it is highly unlikely that all the alloantigens expressed by a cadaver organ donor will be represented in the alloantigen pretreatment inoculum. We have previously shown that it is not necessary to expose the recipient to the full complement of donor alloantigens to induce long-term survival of a subsequent cardiac allograft. Here, we investigated the in vivo mechanism responsible for this phenomena. METHODS: Unresponsiveness to the mouse MHC class I molecule Kb was induced in CBA.Ca (H2k) recipients by administration of bone marrow cells from transgenic CBA mice, CBK (H2k + Kb) before transplantation of fully allogeneic and F1 vascularized cardiac allografts. RESULTS: Pretreatment with CBK bone marrow cells resulted in the long-term survival of all cardiac allografts expressing H2-Kb. For example, C57BL/10 (H2b) and (CBKxBALB/c) F1 (H2k,d + Kb) cardiac allografts were accepted by recipients treated with CBK bone marrow cells before transplantation. In contrast, allografts that did not express Kb, such as BALB/c (H2d) or (CBAxBALB/c) F1 (H2k,d), were rejected acutely, with a median survival time (MST) of 7 and 6 days, respectively, in recipients treated with CBK bone marrow cells. Furthermore, when recipients pretreated with CBK bone marrow cells were grafted with a BALB/c heart and a CBK heart simultaneously, the BALB/c hearts were rejected (MST=10 days), whereas the CBK hearts were accepted. By contrast, in the maintenance phase (i.e., after transplantation), recipients with long-term surviving (CBKxBALB/c) F1 hearts (> 100 days) were found to accept BALB/c hearts indefinitely, whereas fourth-party B10.S (H2s) grafts were rejected (MST=7.5 days). This indicated that the allografts bearing Kb could tolerize recipients to other alloantigens expressed by the transplanted heart. CONCLUSIONS: These data provide clear evidence for linked epitope suppression in the induction of operational tolerance in vivo.
BACKGROUND: Allograft survival can be prolonged by the administration of alloantigen(s) before transplantation. Blood transfusion is the commonest form of alloantigen pretreatment currently used in clinical practice. However, for recipients of organs from cadaver donors, it is not possible to predict the identity of the organ donor in advance. Therefore, it is highly unlikely that all the alloantigens expressed by a cadaver organ donor will be represented in the alloantigen pretreatment inoculum. We have previously shown that it is not necessary to expose the recipient to the full complement of donor alloantigens to induce long-term survival of a subsequent cardiac allograft. Here, we investigated the in vivo mechanism responsible for this phenomena. METHODS: Unresponsiveness to the mouse MHC class I molecule Kb was induced in CBA.Ca (H2k) recipients by administration of bone marrow cells from transgenic CBA mice, CBK (H2k + Kb) before transplantation of fully allogeneic and F1 vascularized cardiac allografts. RESULTS: Pretreatment with CBK bone marrow cells resulted in the long-term survival of all cardiac allografts expressing H2-Kb. For example, C57BL/10 (H2b) and (CBKxBALB/c) F1 (H2k,d + Kb) cardiac allografts were accepted by recipients treated with CBK bone marrow cells before transplantation. In contrast, allografts that did not express Kb, such as BALB/c (H2d) or (CBAxBALB/c) F1 (H2k,d), were rejected acutely, with a median survival time (MST) of 7 and 6 days, respectively, in recipients treated with CBK bone marrow cells. Furthermore, when recipients pretreated with CBK bone marrow cells were grafted with a BALB/c heart and a CBK heart simultaneously, the BALB/c hearts were rejected (MST=10 days), whereas the CBK hearts were accepted. By contrast, in the maintenance phase (i.e., after transplantation), recipients with long-term surviving (CBKxBALB/c) F1 hearts (> 100 days) were found to accept BALB/c hearts indefinitely, whereas fourth-party B10.S (H2s) grafts were rejected (MST=7.5 days). This indicated that the allografts bearing Kb could tolerize recipients to other alloantigens expressed by the transplanted heart. CONCLUSIONS: These data provide clear evidence for linked epitope suppression in the induction of operational tolerance in vivo.
Authors: Kenneth K Wong; Matthew J Carpenter; Lesley L Young; Susan J Walker; Grahame McKenzie; Alyson J Rust; George Ward; Laura Packwood; Karen Wahl; Luc Delriviere; Gerard Hoyne; Paul Gibbs; Brian R Champion; Jonathan R Lamb; Margaret J Dallman Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Adam D Griesemer; John C Lamattina; Masayoshi Okumi; Justin D Etter; Akira Shimizu; David H Sachs; Kazuhiko Yamada Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Luis Graca; Alain Le Moine; Chun-Yen Lin; Paul J Fairchild; Stephen P Cobbold; Herman Waldmann Journal: Proc Natl Acad Sci U S A Date: 2004-06-24 Impact factor: 11.205
Authors: K Brown; A Badar; K Sunassee; M A Fernandes; H Shariff; S Jurcevic; P J Blower; S H Sacks; G E D Mullen; W Wong Journal: Am J Transplant Date: 2011-01-10 Impact factor: 8.086
Authors: Toshiro Ito; Akira Yamada; Ibrahim Batal; Melissa Y Yeung; Martina M McGrath; Mohamed H Sayegh; Anil Chandraker; Takuya Ueno Journal: Front Immunol Date: 2016-03-09 Impact factor: 7.561
Authors: Lindsey A Edwards; Anna K Nowocin; Nazila V Jafari; Lucy L Meader; Kathryn Brown; Aurélien Sarde; Carolyn Lam; Alex Murray; Wilson Wong Journal: Circulation Date: 2017-08-03 Impact factor: 29.690